Short Interest in Boston Scientific Corporation (NYSE:BSX) Expands By 83.0%

Posted by Geri Gentry on Jun 17th, 2026

Boston Scientific logo Boston Scientific Corporation (NYSE:BSX – Get Free Report) saw a large growth in short interest in May. As of May 29th, there was short interest totaling 57,491,117 shares, a growth of 83.0% from the May 14th total of 31,423,298 shares. Based on an average daily trading volume, of 25,507,630 shares, the days-to-cover ratio is currently 2.3 days. Approximately 3.9% of the shares of the company are short sold.

Analyst Ratings Changes

Several brokerages have issued reports on BSX. Daiwa Securities Group cut Boston Scientific from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. UBS Group dropped their target price on Boston Scientific from $120.00 to $105.00 and set a “buy” rating on the stock in a research report on Tuesday, March 17th. Wells Fargo & Company reissued an “equal weight” rating and issued a $55.00 target price (down from $75.00) on shares of Boston Scientific in a research report on Thursday, May 28th. Raymond James Financial reissued an “outperform” rating and issued a $88.00 target price (down from $97.00) on shares of Boston Scientific in a research report on Monday, March 30th. Finally, Leerink Partners dropped their target price on Boston Scientific from $87.00 to $74.00 and set an “outperform” rating on the stock in a research report on Thursday, May 28th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Boston Scientific presently has a consensus rating of “Moderate Buy” and a consensus price target of $85.08.

Get Our Latest Analysis on BSX

Insider Buying and Selling

In other news, Director David C. Habiger bought 2,250 shares of the company’s stock in a transaction on Wednesday, May 20th. The shares were acquired at an average cost of $55.92 per share, with a total value of $125,820.00. Following the completion of the transaction, the director owned 13,878 shares of the company’s stock, valued at approximately $776,057.76. This trade represents a 19.35% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Edward J. Ludwig bought 3,580 shares of the company’s stock in a transaction on Wednesday, May 20th. The stock was purchased at an average cost of $56.68 per share, for a total transaction of $202,914.40. Following the completion of the transaction, the director directly owned 25,359 shares of the company’s stock, valued at approximately $1,437,348.12. The trade was a 16.44% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders acquired 9,800 shares of company stock worth $554,012. 0.34% of the stock is owned by corporate insiders.

Institutional Trading of Boston Scientific

Several institutional investors and hedge funds have recently added to or reduced their stakes in BSX. Murphy & Mullick Capital Management Corp raised its stake in Boston Scientific by 200.0% during the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 170 shares during the period. FWL Investment Management LLC bought a new stake in Boston Scientific in the 2nd quarter worth approximately $26,000. Swiss RE Ltd. bought a new stake in Boston Scientific in the 4th quarter worth approximately $26,000. Garton & Associates Financial Advisors LLC purchased a new position in Boston Scientific during the 4th quarter valued at $26,000. Finally, Colonial Trust Co SC lifted its stake in shares of Boston Scientific by 502.2% during the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 231 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Up 0.3%

BSX stock opened at $46.92 on Wednesday. Boston Scientific has a twelve month low of $45.99 and a twelve month high of $109.50. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. The stock has a market cap of $69.74 billion, a P/E ratio of 19.63, a PEG ratio of 0.89 and a beta of 0.56. The business’s 50-day moving average price is $55.74 and its 200-day moving average price is $74.02.

Boston Scientific (NYSE:BSX – Get Free Report) last posted its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The firm had revenue of $5.20 billion for the quarter, compared to analysts’ expectations of $5.19 billion. During the same period in the previous year, the firm earned $0.75 EPS. The business’s quarterly revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, equities research analysts forecast that Boston Scientific will post 3.36 EPS for the current year.

Boston Scientific announced that its Board of Directors has initiated a stock repurchase plan on Monday, May 18th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares buyback plans are often a sign that the company’s management believes its shares are undervalued.

About Boston Scientific

(Get Free Report)

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.